These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 3067340

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL, Campbell BJ, Dwarakanath AD, Yaqoob M, Stevenson A, Morris AI, Rhodes JM.
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G, Florholmen J.
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [Abstract] [Full Text] [Related]

  • 5. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
    Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K.
    Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
    [Abstract] [Full Text] [Related]

  • 6. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K, Becker K, Ueberschaer B.
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [Abstract] [Full Text] [Related]

  • 7. Evolution of olsalazine.
    Truelove SC.
    Scand J Gastroenterol Suppl; 1988 Apr; 148():3-6. PubMed ID: 2906475
    [Abstract] [Full Text] [Related]

  • 8. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N, Weir DG, Kelleher D.
    Ir J Med Sci; 1999 Apr; 168(4):228-32. PubMed ID: 10624358
    [Abstract] [Full Text] [Related]

  • 9. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
    Karamanolis DG, Papatheodoridis GV, Xourgias V.
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
    [Abstract] [Full Text] [Related]

  • 10. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW, Gales BJ.
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [Abstract] [Full Text] [Related]

  • 11. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
    Ewe K, Eckardt V, Kanzler G.
    Scand J Gastroenterol Suppl; 1988 Jun; 148():70-5. PubMed ID: 2906479
    [Abstract] [Full Text] [Related]

  • 12. A mesalazine enema for ulcerative colitis.
    Drug Ther Bull; 1994 May 19; 32(5):38-9. PubMed ID: 7635028
    [Abstract] [Full Text] [Related]

  • 13. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
    Birketvedt GS, Berg KJ, Fausa O, Florholmen J.
    Inflamm Bowel Dis; 2000 Nov 19; 6(4):275-9. PubMed ID: 11149559
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of olsalazine and its metabolites.
    van Hogezand RA.
    Scand J Gastroenterol Suppl; 1988 Nov 19; 148():17-20. PubMed ID: 2906473
    [Abstract] [Full Text] [Related]

  • 15. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
    Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG.
    Lancet; 1992 May 23; 339(8804):1279-81. PubMed ID: 1349676
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.